Jaguar Health Leverages AI to Cut Parenteral Support by 37% and Pursue Breakthrough Therapy
Jaguar Health plans to deploy AI data mining platforms to accelerate crofelemer’s FDA approval process for pediatric microvillus inclusion disease by linking genetics, histopathology and real-world symptom data. Reported up to 37% parenteral support reduction in MVID trials, seeks Breakthrough Therapy designation with access to an $8 billion market by 2033.
1. AI Integration for Crofelemer Programs
Jaguar Health plans to deploy machine learning and data mining platforms to link genetics, histopathology and real-world symptom data for personalized crofelemer regimens in adult and pediatric intestinal failure patients.
2. Clinical Milestones and Market Potential
The company reported an investigator-sponsored microvillus inclusion disease trial achieved up to 37% reduction in parenteral support, while projecting an $8.0 billion market for short bowel syndrome and intestinal failure by 2033.
3. Regulatory and Funding Strategy
Jaguar is pursuing Breakthrough Therapy designation from the U.S. Food and Drug Administration and is in discussions for non-dilutive funding to accelerate commercialization of crofelemer in rare gastrointestinal disorders.